Related Experiment Video
Updated: Mar 16, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Subsidised access to new melanoma drugs: in need of further innovation?
Michael Wonder1, Rosalie Fisher2
1Wonder Drug Consulting Pty Ltd, Cronulla, Australia.
Aims:
Melanoma is the most serious of the three common forms of skin cancer. New Zealand and Australia have the highest melanoma incidence rate in the world. A number of new treatments for melanoma with different modes of action have recently become available. Our aim was to examine their availability and subsidized access in New Zealand and to compare their availability and access in Australia and England.
Methods:
We examined the clinical evidence base of the new treatments, their place in treatment guidelines and their consideration for reimbursement by PHARMAC in New Zealand, the PBAC in Australia and NICE in England.
Results:
The PBAC and NICE have recommended most treatments and their recommendations have been implemented promptly, using innovative access and pricing models. PHARMAC has rejected most of the new treatments and none has been funded. Pembrolizumab has been recommended with a low priority.
Conclusions:
New Zealand should not be in the unenviable position whereby it has the highest incidence of a fatal disease yet is the last country in the Western world to fund effective treatments for it. We offer recommendations to all stakeholders to break the current access impasse.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

